Revance Therapeutics Inc (RVNC)
3.995
+0.04
(+1.14%)
USD |
NASDAQ |
May 06, 15:16
Revance Therapeutics Shareholders Equity (Quarterly): -151.60M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -151.60M |
| September 30, 2023 | -106.20M |
| June 30, 2023 | 26.79M |
| March 31, 2023 | -26.67M |
| December 31, 2022 | 12.60M |
| September 30, 2022 | 145.71M |
| June 30, 2022 | -2.631M |
| March 31, 2022 | 25.54M |
| December 31, 2021 | 68.47M |
| September 30, 2021 | 120.16M |
| June 30, 2021 | 186.24M |
| March 31, 2021 | 244.25M |
| December 31, 2020 | 374.29M |
| September 30, 2020 | 372.85M |
| June 30, 2020 | 255.72M |
| March 31, 2020 | 308.38M |
| December 31, 2019 | 225.49M |
| September 30, 2019 | 151.28M |
| June 30, 2019 | 188.54M |
| March 31, 2019 | 221.10M |
| December 31, 2018 | 145.62M |
| September 30, 2018 | 182.10M |
| Date | Value |
|---|---|
| June 30, 2018 | 209.86M |
| March 31, 2018 | 236.64M |
| December 31, 2017 | 268.84M |
| September 30, 2017 | 142.06M |
| June 30, 2017 | 159.41M |
| March 31, 2017 | 178.67M |
| December 31, 2016 | 177.07M |
| September 30, 2016 | 200.72M |
| June 30, 2016 | 215.78M |
| March 31, 2016 | 236.85M |
| December 31, 2015 | 253.25M |
| September 30, 2015 | 142.36M |
| June 30, 2015 | 148.84M |
| March 31, 2015 | 163.46M |
| December 31, 2014 | 176.37M |
| September 30, 2014 | 187.91M |
| June 30, 2014 | 198.51M |
| March 31, 2014 | 78.69M |
| December 31, 2013 | -157.55M |
| September 30, 2013 | -22.24M |
| December 31, 2012 | -216.73M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-151.60M
Minimum
Dec 2023
374.29M
Maximum
Dec 2020
127.33M
Average
145.71M
Median
Sep 2022
Shareholders Equity (Quarterly) Benchmarks
| AbbVie Inc | 8.007B |
| Alnylam Pharmaceuticals Inc | -219.27M |
| Ionis Pharmaceuticals Inc | 386.69M |
| Madrigal Pharmaceuticals Inc | 405.33M |
| Vertex Pharmaceuticals Inc | 17.58B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 478.45M |
| Total Liabilities (Quarterly) | 630.06M |
| Debt to Equity Ratio | -2.830 |
| Current Ratio | 3.798 |
| Net Debt Paydown Yield | -1.30% |